<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707601</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-366-1992</org_study_id>
    <secondary_id>2014-004545-27</secondary_id>
    <nct_id>NCT02707601</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment</brief_title>
  <acronym>Co-STARs</acronym>
  <official_title>A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) as measured by the
      proportion of participants achieving hepatitis C virus (HCV) RNA below the lower limit of
      quantification (LLOQ) 12 weeks after the last dose of LDV/SOF (sustained virologic response
      (SVR) 12).

      This study will consist of 2 parts. In Part 1, the participants will be randomized to switch
      from stable antiretroviral (ARV) therapy to either E/C/F/TAF or F/R/TAF. The participants
      maintaining HIV-1 RNA &lt; 50 copies/mL and tolerating E/C/F/TAF or F/R/TAF through Part 1 will
      continue to Part 2 where they will receive the LDV/SOF treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">September 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)</measure>
    <time_frame>HCV Posttreatment Week 12</time_frame>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with HCV RNA &lt; LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)</measure>
    <time_frame>HCV Posttreatment Week 4</time_frame>
    <description>SVR4 is defined as HCV RNA &lt; LLOQ at 4 weeks after stopping LDV/SOF treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Participants with HIV-1 RNA ≥ 50 copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm</measure>
    <time_frame>HIV Posttreatment Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 32 weeks plus 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>HIV-1 Infection</condition>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>E/C/F/TAF + LDV/SOF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF.
Part 2: After 8 weeks of E/C/F/TAF treatment, the participants will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F/R/TAF + LDV/SOF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF.
Part 2: After 8 weeks of F/R/TAF treatment, the participants will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E/C/F/TAF</intervention_name>
    <description>E/C/F/TAF (150/150/200/10 mg) fixed dose combination (FDC) tablet administered orally once daily</description>
    <arm_group_label>E/C/F/TAF + LDV/SOF</arm_group_label>
    <other_name>Genvoya®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F/R/TAF</intervention_name>
    <description>F/R/TAF (200/25/25 mg) FDC tablet administered orally once daily</description>
    <arm_group_label>F/R/TAF + LDV/SOF</arm_group_label>
    <other_name>Odefsey®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF</intervention_name>
    <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily</description>
    <arm_group_label>E/C/F/TAF + LDV/SOF</arm_group_label>
    <arm_group_label>F/R/TAF + LDV/SOF</arm_group_label>
    <other_name>Harvoni®</other_name>
    <other_name>GS-5885/GS-7977</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Chronic genotype (GT) 1, HCV infected, male and non-pregnant/ non-lactating female
             individuals, without cirrhosis, treatment-naive or treatment-experienced with
             interferon (IFN) +/- ribavirin (RBV) +/- HCV protease inhibitor (PI). Compensated
             cirrhotic individuals must be HCV treatment-naive. No prior treatments with NS5A and
             NS5B or any HCV direct acting antivirals, except boceprevir, telaprevir and
             simeprevir, in combination with IFN and RBV

          -  Currently on an ARV regimen (2 NRTI + a third agent) without change for 6 months prior
             to screening. Documented plasma HIV-1 RNA levels &lt; 50 copies/mL (or undetectable HIV-1
             RNA level according to the local assay being used if the limit of detection is ≥ 50
             copies/mL) for ≥ 6 months preceding the screening visit. After reaching HIV-1 RNA &lt; 50
             copies/mL, single values (&quot;blips&quot;) of HIV-1 RNA ≥ 50 copies/mL followed by
             resuppression is allowed. For individuals with 3 or more prior ARV regimens, a regimen
             history should be provided for approval by the Sponsor.

               -  Note: Individuals that changed from TDF to TAF less than 6 months ago will be
                  eligible as long as the TDF/ TAF change was the only change to the regimen.

          -  Plasma HIV-1 RNA level &lt; 50 copies/mL at the screening visit

          -  Have no documented resistance to any of the HIV study agents at time in the past,
             including but not limited to the reverse transcriptase resistance mutations K65R,
             K70E, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C, M230I/L,
             the combination of K103N+L100I, or 3 or more thymidine analog associated mutations
             (TAMs) that include M41L or L210W (TAMs are M41L, D67N, K70R, L210W, T215Y/F,
             K219Q/E/N/R). If a historical genotype prior to first ARV is not available or
             individual had 3 or more prior ARV regimens, individual will have proviral genotype
             analysis for archived resistance prior to Day 1.

          -  No history of HIV virologic failure

          -  No evidence of Hepatitis B infection

          -  Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min as estimated by
             Cockcroft-Gault formula

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Medical Group</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mills Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter J Ruane MD Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The George Washington University Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitman-Walker Health</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community AIDS Network</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therafirst Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midway Immunology &amp; Research Center, LLC</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Healthcare Foundation</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Healthcare Foundation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josephs Comprehensive Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowan Tree Medical PA</name>
      <address>
        <city>Wilton Manors</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatham County Health Department</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The CORE Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Free Health Clinic</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network, Network Office of Research and Innovation</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia FIGHT</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon E. Crofoot MD PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Concepts, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Alliance for Research &amp; Education</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Shalit MD</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Cal</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Health Care</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico Inc</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HCV</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>HCV direct acting antiviral(s) (DAA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

